Published in Transplantation on September 15, 2003
Delayed graft function in the kidney transplant. Am J Transplant (2011) 2.06
Molecular mediators of liver ischemia and reperfusion injury: a brief review. Mol Med (2008) 1.43
Ischaemia-reperfusion injury in liver transplantation--from bench to bedside. Nat Rev Gastroenterol Hepatol (2012) 1.39
Composite tissue allotransplantation of the face: Decision analysis model. Can J Plast Surg (2007) 0.91
Thymoglobulin induction dosing strategies in a low-risk kidney transplant population: three or four days? J Transplant (2010) 0.90
New directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunity. Drugs (2014) 0.84
A randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes. Transplantation (2015) 0.83
Current state of renal transplant immunosuppression: Present and future. World J Transplant (2012) 0.81
Antibody induction therapy in adult kidney transplantation: A controversy continues. World J Transplant (2012) 0.81
Immunophenotyping and efficacy of low dose ATG in non-sensitized kidney recipients undergoing early steroid withdrawal: a randomized pilot study. PLoS One (2014) 0.80
Immunomodulation with rabbit anti-thymocyte globulin in solid organ transplantation. World J Transplant (2015) 0.78
Monoclonal antibody therapy and renal transplantation: focus on adverse effects. Toxins (Basel) (2014) 0.77
Ischemia and reperfusion injury in renal transplantation: hemodynamic and immunological paradigms. Einstein (Sao Paulo) (2015) 0.77
Kidney and liver transplants from donors after cardiac death: initial experience at the London Health Sciences Centre. Can J Surg (2010) 0.76
Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation. J Transplant (2012) 0.75
Perioperative effects of high doses of intraoperative thymoglobulin induction in liver transplantation. World J Transplant (2015) 0.75
Prolonged lymphopenia following anti-thymocyte globulin induction is associated with decreased long-term graft survival in liver transplant recipients. Hippokratia (2012) 0.75
A Double-Blind, Double-Dummy, Flexible-Design Randomized Multicenter Trial: Early Safety of Single- Versus Divided-Dose Rabbit Anti-Thymocyte Globulin Induction in Renal Transplantation. Am J Transplant (2016) 0.75
Timing of rabbit antithymocyte globulin induction therapy in kidney transplantation: an observational cohort study. Transplant Res (2014) 0.75
Induction by anti-thymocyte globulins in kidney transplantation: a review of the literature and current usage. J Nephropathol (2015) 0.75
A Proposal for Early Dosing Regimens in Heart Transplant Patients Receiving Thymoglobulin and Calcineurin Inhibition. Transplant Direct (2016) 0.75
Optimizing Graft Survival by Pretreatment of the Donor. Clin J Am Soc Nephrol (2017) 0.75
The influence of induction therapy for kidney transplantation after a non-renal transplant. Clin J Am Soc Nephrol (2011) 0.75
Biologics in the prevention and treatment of graft rejection. Springer Semin Immunopathol (2006) 0.75
Comparative efficacy and safety of antibody induction therapy for the treatment of kidney: a network meta-analysis. Oncotarget (2017) 0.75
International trial of the Edmonton protocol for islet transplantation. N Engl J Med (2006) 13.43
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med (2007) 9.51
HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med (2008) 7.42
Strategies to improve long-term outcomes after renal transplantation. N Engl J Med (2002) 6.76
Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med (2006) 5.42
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med (2003) 4.20
Donor characteristics associated with reduced graft survival: an approach to expanding the pool of kidney donors. Transplantation (2002) 3.42
The ethics statement of the Vancouver Forum on the live lung, liver, pancreas, and intestine donor. Transplantation (2006) 3.24
Morbidity and mortality after living kidney donation, 1999-2001: survey of United States transplant centers. Am J Transplant (2003) 2.95
The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol (2011) 2.69
Case records of the Massachusetts General Hospital. Case 15-2009. A 25-year-old man with coma after cardiac arrest. N Engl J Med (2009) 2.65
A report of the Vancouver Forum on the care of the live organ donor: lung, liver, pancreas, and intestine data and medical guidelines. Transplantation (2006) 2.55
CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. Am J Transplant (2004) 2.45
The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol (2011) 2.34
Expanded criteria donors for kidney transplantation. Am J Transplant (2003) 2.25
Early outcomes among those initiating chronic dialysis in the United States. Clin J Am Soc Nephrol (2011) 2.17
National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant (2004) 2.01
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol (2006) 2.00
Host alloreactive memory T cells influence tolerance to kidney allografts in nonhuman primates. Sci Transl Med (2011) 1.97
Living-donor kidney transplantation: a review of the current practices for the live donor. J Am Soc Nephrol (2005) 1.93
Increased transplanted organs from the use of a standardized donor management protocol. Am J Transplant (2002) 1.92
Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol (2002) 1.84
Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci U S A (2008) 1.83
Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates. Transplantation (2004) 1.82
New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet (2012) 1.79
Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) conference. Clin J Am Soc Nephrol (2008) 1.76
Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation (2002) 1.75
Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. Kidney Int (2011) 1.73
Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis. Kidney Int (2002) 1.72
Biology of desmoplastic melanoma: a case-control comparison with other melanomas. J Clin Oncol (2005) 1.71
Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2005) 1.70
Donation after cardiac death as a strategy to increase deceased donor liver availability. Ann Surg (2006) 1.66
Living kidney donors in need of kidney transplants: a report from the organ procurement and transplantation network. Transplantation (2002) 1.65
Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. J Immunol (2005) 1.62
Significance of anticardiolipin antibodies on short and long term allograft survival and function following kidney transplantation. Am J Transplant (2004) 1.54
Liver transplantation for malignancy. Oncologist (2005) 1.54
Reproduction and transplantation: report on the AST Consensus Conference on Reproductive Issues and Transplantation. Am J Transplant (2005) 1.52
Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance. Liver Transpl (2008) 1.50
Clinical role of the renal transplant biopsy. Nat Rev Nephrol (2012) 1.46
Aggressive pharmacologic donor management results in more transplanted organs. Transplantation (2003) 1.45
Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. Am J Transplant (2002) 1.44
Role of CXC chemokine receptor 3 pathway in renal ischemic injury. J Am Soc Nephrol (2006) 1.44
The consequences of public policy to buy and sell organs for transplantation. Am J Transplant (2004) 1.43
No difference in transplant outcomes for local and import pancreas allografts. Transplantation (2009) 1.43
A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation (2003) 1.41
Complex arterial reconstruction for pancreas transplantation in recipients with advanced arteriosclerosis. Transplantation (2007) 1.39
Penis Transplantation: First US Experience. Ann Surg (2017) 1.38
Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts. Proc Natl Acad Sci U S A (2007) 1.35
Promotion of altruistic donation. Transplantation (2009) 1.33
HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med (2013) 1.29
Mixed chimerism, lymphocyte recovery, and evidence for early donor-specific unresponsiveness in patients receiving combined kidney and bone marrow transplantation to induce tolerance. Transplantation (2010) 1.25
The case for pancreas after kidney transplantation. Clin Transplant (2009) 1.23
Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation (2004) 1.22
Peripheral expression of self-MHC-II influences the reactivity and self-tolerance of mature CD4(+) T cells: evidence from a lymphopenic T cell model. Immunity (2002) 1.22
Summary report of a national conference: Evolving concepts in liver allocation in the MELD and PELD era. December 8, 2003, Washington, DC, USA. Liver Transpl (2004) 1.19
Differential role of CCR2 in islet and heart allograft rejection: tissue specificity of chemokine/chemokine receptor function in vivo. J Immunol (2004) 1.19
Hormonal resuscitation yields more transplanted hearts, with improved early function. Transplantation (2003) 1.18
Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation. Transpl Int (2005) 1.17
Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy. Circulation (2008) 1.16
The report of a national conference on the wait list for kidney transplantation. Am J Transplant (2003) 1.14
Immuno-intervention for the induction of transplantation tolerance through mixed chimerism. Semin Immunol (2011) 1.12
Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. Transplantation (2011) 1.12
Impact of the expanded criteria donor allocation system on the use of expanded criteria donor kidneys. Transplantation (2005) 1.10
Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma. Br J Haematol (2014) 1.10
Effect of mixed hematopoietic chimerism on cardiac allograft survival in cynomolgus monkeys. Transplantation (2002) 1.10
Preclinical and clinical studies on the induction of renal allograft tolerance through transient mixed chimerism. Curr Opin Organ Transplant (2011) 1.10
Pharmacoepidemiology of anemia in kidney transplant recipients. J Am Soc Nephrol (2004) 1.07
CD70 signaling is critical for CD28-independent CD8+ T cell-mediated alloimmune responses in vivo. J Immunol (2005) 1.06
Treatment of recurrent allograft dysfunction with intravenous hematin after liver transplantation for erythropoietic protoporphyria. Transplantation (2002) 1.05
Mechanism of action of donor-specific transfusion in inducing tolerance: role of donor MHC molecules, donor co-stimulatory molecules, and indirect antigen presentation. J Am Soc Nephrol (2004) 1.05
Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation. Transplantation (2009) 1.05
Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. Clin J Am Soc Nephrol (2010) 1.04
The role of CC chemokine receptor 5 (CCR5) in islet allograft rejection. Diabetes (2002) 1.04
Organ donation and utilization in the USA. Am J Transplant (2004) 1.03
The Immune Tolerance Network at 10 years: tolerance research at the bedside. Nat Rev Immunol (2010) 1.03
Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant (2003) 1.03
Pathology of an islet transplant 2 years after transplantation: evidence for a nonimmunological loss. Transplantation (2008) 1.03